Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Olaparib + Pembrolizumab in TNBC or HR+ HER2- Breast Cancer with Germline Mutations
NCT05203445Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2022
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, pembrolizumab in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2022; status: active, not recruiting.
02
Drugs
olaparibpembrolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05203445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203445.